Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.

[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.

[5] In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.

[6] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.